What is Spectrum Pharmaceuticals (SPPI) stock's ticker?
Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI.". Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) issued its quarterly earnings data on Thursday, August, 9th. The biotechnology company reported ($0.21) EPS for the quarter, topping the Zacks' consensus estimate of ($0.23) by $0.02.
Where can I buy SPPI shares?
Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Spectrum Pharmaceuticals' stock price today?
What are analysts'target prices for Spectrum Pharmaceuticals (SPX) stock?
2 Wall Street analysts have issued 1 year target prices for Spectrum Pharmaceuticals' shares. Their forecasts range from $4.00 to $6.00. On average, they anticipate Spectrum Pharmaceuticals' stock price to reach $5.00 in the next year.
Is the heavy selling pressure exhausted for spectrum Pharma (SPPI)?
Investors need to pay close attention to Spectrum Pharmaceuticals (SPPI) stock based on the movements in the options market lately. The heavy selling pressure might have exhausted for Spectrum Pharma (SPPI) as it is technically in oversold territory now.
Should I buy Spectrum Pharmaceuticals stock?
There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Spectrum Pharmaceuticals stock.
Did Sppi get FDA approval?
--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that its New Drug Application (NDA) for poziotinib has been accepted for review by the U.S. Food and Drug Administration (FDA).
Why did SPPI stock drop?
The big decline came after the company announced that the U.S. Food and Drug Administration turned down approval of Rolontis in treating neutropenia in patients receiving cancer drugs that decrease bone marrow activity.
When did Spectrum Pharmaceuticals go public?
Spectrum Pharmaceuticals Completes $42 Million Public Offering With Leading Biotech Institutional Investors. IRVINE, Calif., Sept 19, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Spectrum Pharmaceuticals, Inc.
Will SPPI stock recover?
On average, analysts forecast that SPPI's EPS will be -$0.51 for 2022, with the lowest EPS forecast at -$0.62, and the highest EPS forecast at -$0.37. On average, analysts forecast that SPPI's EPS will be -$0.07 for 2023, with the lowest EPS forecast at -$0.18, and the highest EPS forecast at $0.06.
Who owns SPPI stock?
Top 10 Owners of Spectrum Pharmaceuticals IncStockholderStakeShares ownedBlackRock Fund Advisors7.12%12,817,131D. E. Shaw & Co. LP4.36%7,845,726The Vanguard Group, Inc.4.25%7,646,403SSgA Funds Management, Inc.1.85%3,338,3166 more rows
Did Rolontis get approved?
The FDA turned down Rolontis' application to treat neutropenia in cancer patients on myelosuppressive therapies. In a complete response letter, the FDA raised issues with manufacturing “deficiencies” and flagged the need for a site reinspection, Spectrum said in a release.
Where is Spectrum Pharmaceuticals located?
Irvine, CaliforniaSpectrum Pharmaceuticals is an American biopharmaceutical company. The company is located in Irvine, California.
What does Sppi stand for?
Definition. SPPI. Solely Payments of Principal and Interest (finance)
What is Rolontis?
Rolontis (eflapegrastim) is an investigational granulocyte-colony stimulating factor (G-CSF) analog in development as a treatment for chemotherapy-induced neutropenia.
What is FDA Pdufa date?
Prescription Drug User Fee Act (PDUFA) dates refer to deadlines for the FDA to review new drugs. The PDUFA date is 10 months after the drug application has been accepted by the FDA or 6 months, if the drug is given a priority review designation.
Should I buy or sell Spectrum Pharmaceuticals stock right now?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last twelve months. There are currently 1...
What is Spectrum Pharmaceuticals' stock price forecast for 2022?
4 analysts have issued 1-year price objectives for Spectrum Pharmaceuticals' stock. Their SPPI stock forecasts range from $4.00 to $10.00. On avera...
How has Spectrum Pharmaceuticals' stock performed in 2022?
Spectrum Pharmaceuticals' stock was trading at $1.27 at the start of the year. Since then, SPPI stock has decreased by 35.4% and is now trading at...
When is Spectrum Pharmaceuticals' next earnings date?
Spectrum Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecas...
How were Spectrum Pharmaceuticals' earnings last quarter?
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) posted its quarterly earnings results on Thursday, March, 17th. The biotechnology company reported ($0...
Who are Spectrum Pharmaceuticals' key executives?
Spectrum Pharmaceuticals' management team includes the following people: Mr. Thomas J. Riga , Pres, CEO & Director (Age 46, Pay $1.03M) ( Linked...
What is Joseph Turgeon's approval rating as Spectrum Pharmaceuticals' CEO?
2 employees have rated Spectrum Pharmaceuticals CEO Joseph Turgeon on Glassdoor.com . Joseph Turgeon has an approval rating of 47% among Spectrum...
Who are some of Spectrum Pharmaceuticals' key competitors?
Some companies that are related to Spectrum Pharmaceuticals include Amgen (AMGN) , Gilead Sciences (GILD) , Vertex Pharmaceuticals (VRTX) , Reg...
What other stocks do shareholders of Spectrum Pharmaceuticals own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Phar...
When is Spectrum Pharmaceuticals' earnings call 2021?
Who is the CEO of Spectrum Pharmaceuticals?
(NASDAQ:SPPI) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 13, 2021 at 4:30 PM Eastern Time.
When will Spectrum Pharmaceuticals release its earnings?
Joining me on the call today from Spectrum Pharmaceuticals will be Joe Turgeon, President and CEO, and Dr. Francois Lebel, Chief Medical Officer.
How much does Spectrum Pharmaceuticals make?
Spectrum Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021. View our earnings forecast for Spectrum Pharmaceuticals.
Nasdaq Global Select
How much money does Spectrum Pharmaceuticals make? Spectrum Pharmaceuticals has a market capitalization of $676.77 million and generates $109.33 million in revenue each year. The biotechnology company earns $-160,870,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis.
Environmental, Social, and Governance Rating
A biopharmaceutical company that acquires and advances a diversified portfolio of drug candidates, with a focus on oncology, urology and other critical health challenges for which there are few other treatment options.
Business Summary
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
